BWAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brainsway Ltd (BWAY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive revenue and net income growth in its latest quarter and has received FDA approval for a promising product, the technical indicators are mixed, with no clear bullish momentum. Additionally, the stock lacks strong trading signals, and the recent price trend is slightly negative. Given these factors, it is better to hold off on buying until clearer positive trends emerge.
The technical indicators are mixed. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 49.421, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level (S1: 13.069), with resistance at R1: 14.23. However, the overall price trend has been slightly negative, with a -2.67% regular market change and a -0.30% post-market change.
FDA approval for the Proliv™ RX system, which targets treatment-resistant major depressive disorder.
A $6 million investment in Neurolief, showing confidence in the company's growth potential.
Revenue increased by 28.66% YoY, and net income surged by 136.56% YoY in the latest quarter.
EPS and gross margin dropped to 0, indicating profitability challenges.
Analysts have lowered the price target from $30 to $15, reflecting a more cautious outlook.
No significant hedge fund or insider trading activity, suggesting a lack of strong institutional confidence.
In 2025/Q3, Brainsway reported a 28.66% YoY revenue increase to $13,512,000 and a 136.56% YoY net income increase to $1,566,000. However, EPS and gross margin dropped to 0, highlighting profitability concerns.
Analysts maintain a Buy rating but have lowered the price target from $30 to $15 due to changes in ADS-to-ordinary share ratio. Analysts are optimistic about the medium- to long-term outlook, citing the FDA approval and strategic partnerships as positive drivers.
